Why did ALMDT.PA stock jump intraday today?

Median Technologies received FDA clearance for a lung cancer AI tool, triggering heavy buying and volume of **1,388,702.00** shares on EURONEXT. The regulatory news lifted expectations for commercial partnerships and trial demand.

What are the main risks for ALMDT.PA stock after the rally?

Key risks include continued negative EPS **-1.16**, tight liquidity with current ratio **0.35**, and reliance on successful commercial adoption. Failure to convert approvals into revenue would pressure the stock.

How does Meyka AI view ALMDT.PA stock?

Meyka AI rates ALMDT.PA with a score out of 100: **69.04** (Grade B, HOLD). The grade blends sector, financials, forecasts and analyst inputs; it is informational and not financial advice.

What is the short and medium-term price outlook for ALMDT.PA?

Near term a momentum target is **€7.50**; a 12-month base case sits at **€3.50**. Meyka AI's forecast model projects yearly **€2.91**, which is a model-based projection and not a guarantee.

EU Stocks

ALMDT.PA up 43.66% intraday on FDA clearance 09 Feb 2026: volume tells the story

ByDanny Kontos February 9, 2026

The ALMDT.PA stock jumped to €6.17 intraday on 09 Feb 2026 after FDA clearance for a lung cancer AI tool, driving a heavy trading session on EURONEXT in Europe. Volume surged to 1,388,702.00 shares, well above the 357,588.00 average, and the price range hit a day low of €4.90 and a day high of €6.17. The move follows the company’s product approval news and a fresh wave of buy-side attention. We examine the price drivers, technical setup, valuation metrics, and model forecasts to show what traders should watch next.